Evaxion Biotech A/S

2.52
-0.09 (-3.45%)
At close: Feb 14, 2025, 3:59 PM
2.55
0.99%
After-hours Feb 14, 2025, 05:34 PM EST
undefined%
Bid 2.47
Market Cap 791.15K
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -14
PE Ratio (ttm) -0.18
Forward PE n/a
Analyst Buy
Ask 2.68
Volume 1,463,321
Avg. Volume (20D) 2,376,057
Open 2.61
Previous Close 2.61
Day's Range 2.43 - 2.79
52-Week Range 2.22 - 22.50
Beta undefined

About EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol EVAX

Analyst Forecast

According to 3 analyst ratings, the average rating for EVAX stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 454.46% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Evaxion Biotech A/S is scheduled to release its earnings on Mar 26, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-8.56%
Evaxion Biotech shares are trading lower. The stoc... Unlock content with Pro Subscription
2 weeks ago
-27.14%
Evaxion Biotech shares are trading lower after the company announced a public offering of 3,997,361 ADS.